<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SILDENAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of sildenafil, with risk of hypotension</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with sildenafil at the minimum dose when it is administered with the josamycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SILDENAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of he plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
